Simcere Pharmaceutical Group Announces Resignation of Dr. Peng Wang, Chief Scientific Officer

Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced the resignation of Dr. Peng Wang, Chief Scientific Officer of the Company, effective from May 29, 2013. Dr. Wang resigned for personal reasons. His resignation has been approved by the Company.Mr. Hongquan Liu, the Chief Executive Officer of Simcere, said, "We thank Dr. Wang for his contribution to our research and development efforts and we wish him all the best in the future."About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases, and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.Investor and Media Contacts: Email: ir@simcere.comIn Nanjing:Jie Liu D'EliaVice PresidentSimcere Pharmaceutical GroupTel: 86-25-8556-6666*8857In the United States:Cindy ZhengBrunswick Group LLCTel: 1-212-333-3810 In Beijing:Yue YuBrunswick See full press release